Patent Invalidated: Written Description and Enablement Requirements Sink High-Profile Cancer Drug Dispute

December 2, 2025

Seagen Inc. v. Daiichi Sankyo Co., Ltd. Authored by: Jeremy J. Gustrowsky A recent decision from the Federal Circuit has brought clarity to the requirements for written description and enablement in patent law, with significant implications for pharmaceutical and biotech…

Read More